Bone marrow-derived mesenchymal stem cells for treatment of ischemic cardiomyopathy

The aim of this study is to assess the safety and efficacy of allogenic bone marrow-derived mesenchymal stem cell (BM-MSC) implantation concomitant with left ventricular assist device (LVAD) implantation to treat end-stage ischemic cardiomyopathy.